Product Code: BHP0944SB
“Global Digital PCR Market to Reach $2,847.8 Million by 2032.”
Global Digital PCR Market Industry Overview
The global digital PCR market is projected to reach $2,847.8 million by 2032 from $441.2 million in 2021, at a CAGR of 18.73% during the forecast period 2022-2032. The growth in the global digital PCR market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases globally, the rising awareness of d-PCR-based diagnostic testing, and the significant number of funding for executing research and development.
Market Lifecycle Stage
The global digital PCR market is progressing rapidly with a significant increase in research and development (R&D) activities pertaining to a wide range of d-PCR products for disease detection, accentuating their criticality in healthcare. Digital PCR has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of disease diagnosis. Most players in the global digital PCR market offer products, such as kits and assays, systems, and reagents and consumables.
Increasing investments in R&D for d-PCR molecular diagnostics is one of the major opportunities in the global digital PCR market. Several biotechnology and life sciences companies are working collaboratively on diagnostic test development and using d-PCR as a therapeutic means for applications in several disease indications to enable efficient diagnosis, treatment selection, and treatment monitoring.
Impact of COVID-19
The current global digital PCR market comprises kits and assays, system, and reagents and consumables. The unexpected crisis of the pandemic has surged the demand for essentials and increased the demand for digital PCR products. There was increased demand for digital PCR from biotechnology and life sciences companies. Overall, the impact of COVID-19 on the global d-PCR market size has been low-moderate. Some market players have reported a slight decline in sales. However, some new entrants in the global d-PCR market are expected to witness growth in the market. There is also a decline in revenues mostly due to the initial phases of the COVID-19 pandemic, which comprised complete lockdowns across countries and major cities, thereby interrupting the supply chain. Several other products have been under development for years that may take longer than 2-4 years for commercialization. The pandemic has played a key role in enhancing the growth prospects of digital PCR-based diagnostics and is expected to indirectly aid in improving the market growth outlook.
Market Segmentation:
Segmentation 1: by Product
- Kits and Assays
- Systems
- Reagents and Consumables
The global digital PCR market based on the product segment was dominated by kits and assays in 2021. This is due to an increasing number of research institutes involved in carrying out in vitro diagnostic (IVD) tests in the field of d-PCR-based diagnosis.
Segmentation 2: by Application
- Oncology
- Infectious Diseases
- Rare Diseases
- Gene Expression
- Reproductive Genetics
- Other Applications
In 2021, oncology dominated the application segment of the global digital PCR market.
Segmentation 3: by End User
- Academic and Research Institutions
- Biopharmaceutical Companies
- Diagnostic Centers
- Hospitals and Clinics
The academic and research institutions dominated the end-user segment in the global d-PCR market in 2021, as research laboratories, particularly, are most involved in carrying out research studies focused on identifying and understanding the diagnostic application of digital PCR.
Recent Developments in the Global Digital PCR Market
- In March 2022, Stilla signed an agreement with 12 distributors throughout EMEA. This agreement grants distribution rights to Stilla's full product portfolio, including the six-color naica system.
- In April 2022, Stilla and Promega Corporation signed a co-marketing agreement to offer a complete digital PCR workflow solution to provide their end users with optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assay, overall cancer research, and drug discovery.
- In October 2021, Bio-Rad Laboratories, Inc. acquired Dropworks, Inc., a development stage company focused on developing a digital PCR product. The strategy was to increase and complement the company's life sciences product offerings.
- In September 2021, Thermo Fisher Scientific launched the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results.
Demand - Drivers and Limitations
Following are the demand drivers for the global digital PCR market:
- Technological Transformations Related to Digital PCR
- Rising Adoption of Digital PCR among Various Applications
- Increasing Activities in d-PCR Ecosystem
The market is expected to face some limitations too due to the following challenges:
- Higher Cost of Droplet Digital PCR
- Presence of Opaque Regulatory Framework
How can this report add value to an organization?
- Growth/Marketing Strategy: Owing to the explosion of massively parallel sequencing and its applications, all areas of healthcare have been affected, particularly PCR-based molecular diagnostics. The key components in the digital PCR market consist of a diverse range of d-PCR-based products, generally purchased by the testing companies and the testing services themselves. The entire workflow is well explained in the report, along with pricing analysis considering the applications used in testing.
- Competitive Strategy: Key players in the global d-PCR market analyzed and profiled profiled in the study, consisting of both products-based companies and a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the global digital PCR market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
- Bio-Rad Laboratories, Inc.
- Fluidigm Corporation
- F. Hoffmann-La Roche Ltd.
- Merck KGaA
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
|
- Genetron Holdings Limited
- JN Medsys
- Stilla
- Naveris, Inc.
- SAGA Diagnostics
|
Table of Contents
1 Markets
- 1.1 Product Definition
- 1.1.1 Inclusion and Exclusion
- 1.2 Market Scope
- 1.2.1 Scope of Work
- 1.2.2 Key Questions Answered in the Report
2 Research Methodology
- 2.1 Global Digital PCR Market: Research Methodology
- 2.2 Data Sources
- 2.2.1 Primary Data Sources
- 2.2.2 Secondary Data Sources
- 2.3 Market Estimation Model
- 2.4 Criteria for Company Profiling
3 Market Overview
- 3.1 Market Definition
- 3.2 d-PCR vs. qPCR
- 3.3 Market Footprint and Growth Potential
- 3.4 COVID-19 Impact on the Global Digital PCR Market
- 3.4.1 Impact on Research and Clinical Operations
- 3.4.2 Impact on Market Players
- 3.4.3 Impact on Market Growth
4 Industry Analysis
- 4.1 Overview
- 4.1.1 Regulatory Framework in the U.S.
- 4.1.2 Regulatory Framework in European Union (EU)
- 4.1.3 Regulatory Framework in Asia-Pacific
- 4.1.3.1 Japan
- 4.1.3.2 China
- 4.2 Patent Analysis
- 4.2.1 Patent Analysis (by Region)
- 4.2.2 Patent Analysis (by Country)
- 4.2.3 Patent Analysis (by Year)
5 Market Dynamics
- 5.1 Overview
- 5.2 Impact Analysis
- 5.2.1 Market Drivers
- 5.2.1.1 Technological Transformations Related to Digital PCR
- 5.2.1.2 Rising Adoption of Digital PCR among Various Applications
- 5.2.1.3 Increasing Activities in d-PCR Ecosystem
- 5.2.2 Market Restraints
- 5.2.2.1 Higher Cost of Droplet Digital PCR
- 5.2.2.2 Presence of Opaque Regulatory Framework
- 5.2.3 Market Opportunities
- 5.2.3.1 Extensive Adoption of Genetic Testing, especially in Developing Nations
- 5.2.3.2 Increasing Adoption of d-PCR in Chronic Disease Diagnosis
6 Competitive Landscape
- 6.1 Competitive Landscape
- 6.1.1 Mergers and Acquisitions
- 6.1.2 Synergistic Activities
- 6.1.3 Product Launch and Approval Activities
- 6.1.4 Expansion, Funding, and Other Activities
- 6.1.5 Market-Share Analysis
- 6.1.6 Growth-Share Analysis
- 6.1.6.1 Growth-Share Analysis (by Company)
- 6.1.6.2 Growth-Share Analysis (by Application Type)
- 6.2 Supply Chain Analysis
7 Product
- 7.1 Overview
- 7.1.1 Systems
- 7.1.1.1 Droplet Digital PCR Systems
- 7.1.1.2 Chip-Based Digital PCR Systems
- 7.1.2 Kits and Assays
- 7.1.2.1 Droplet Digital PCR Systems
- 7.1.2.2 Chip-Based Digital PCR
- 7.1.3 Reagents and Consumables
- 7.1.3.1 Droplet Digital PCR
- 7.1.3.2 Chip-Based Digital PCR
8 Application Type
- 8.1 Overview
- 8.1.1 Oncology
- 8.1.1.1 Solid Tumor
- 8.1.1.2 Hematological Malignancies
- 8.1.2 Infectious Diseases
- 8.1.2.1 Respiratory Infections
- 8.1.2.2 Gastrointestinal Infections
- 8.1.2.3 Other Infectious Diseases
- 8.1.3 Rare Diseases
- 8.1.3.1 Inherited Trait Type
- 8.1.3.2 Acquired Trait Type
- 8.1.4 Reproductive Genetics
- 8.1.4.1 Prenatal Diseases
- 8.1.4.2 Postnatal Diseases
- 8.1.5 Gene Expression
- 8.1.6 Other Applications
9 End User
- 9.1 Overview
- 9.1.1 Academic and Research Institutions
- 9.1.2 Hospitals and Clinics
- 9.1.3 Diagnostic Centers
- 9.1.4 Biopharmaceutical Companies
10 Region
- 10.1 Overview
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 France
- 10.3.3 U.K.
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Rest-of-Europe
- 10.4 Asia-Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 Australia
- 10.4.4 South Korea
- 10.4.5 Rest of Asia-Pacific
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest-of-Latin America
- 10.6 Rest-of-the-World (RoW)
- 10.6.1 Middle East
- 10.6.1.1 K.S.A.
- 10.6.1.2 Egypt
- 10.6.1.3 Rest-of-Middle East
- 10.6.2 Africa
11 Company Profiles
- 11.1 Overview
- 11.2 Bio-Rad Laboratories, Inc.
- 11.2.1 Company Overview
- 11.2.2 Role of Bio-Rad Laboratories, Inc. in the Global Digital PCR Market
- 11.2.3 Key Competitors of the Company
- 11.2.4 Key Customers of the Company
- 11.2.5 Synergistic Activities
- 11.2.6 Business Strategies
- 11.2.6.1 Product Launch/Approval
- 11.2.7 Financials
- 11.2.8 Analyst Perspective
- 11.3 Fluidigm Corporation
- 11.3.1 Company Overview
- 11.3.2 Role of Fluidigm Corporation in the Global d- PCR Market
- 11.3.3 Key Competitors of the Company
- 11.3.4 Key Customers of the Company
- 11.3.5 Corporate Strategies
- 11.3.5.1 Synergistic Activities
- 11.3.6 Financials
- 11.3.7 Analyst Perspective
- 11.4 F. Hoffmann-La Roche Ltd.
- 11.4.1 Company Overview
- 11.4.2 Role of F. Hoffmann-La Roche Ltd. in the Global d-PCR Market
- 11.4.3 Key Competitors of the Company
- 11.4.4 Corporate Strategies
- 11.4.4.1 Synergistic Activities
- 11.4.5 Financials
- 11.4.6 Analyst Perspective
- 11.5 Merck KGaA
- 11.5.1 Company Overview
- 11.5.2 Role of Merck KGaA in the Global Digital PCR Market
- 11.5.3 Key Competitors of the Company
- 11.5.4 Financials
- 11.5.5 Analyst Perspective
- 11.6 QIAGEN N.V.
- 11.6.1 Company Overview
- 11.6.2 Role of QIAGEN N.V. in the Global Digital PCR Market
- 11.6.3 Key Competitors of the Company
- 11.6.4 Corporate strategies
- 11.6.4.1 Synergistic Activities
- 11.6.5 Business Strategies
- 11.6.5.1 Product Launch/Approval
- 11.6.6 Financials
- 11.6.7 Analyst Perspective
- 11.7 Thermo Fisher Scientific Inc.
- 11.7.1 Company Overview
- 11.7.2 Role of Thermo Fisher Scientific Inc. in the Global Digital PCR Market
- 11.7.3 Key Competitors of the Company
- 11.7.4 Corporate strategies
- 11.7.4.1 Synergistic Activities
- 11.7.5 Business Strategies
- 11.7.5.1 Product Launch/Approval
- 11.7.6 Financials
- 11.7.7 Analyst Perspective
- 11.8 Genetron Holdings Limited
- 11.8.1 Company Overview
- 11.8.2 Role of Genetron Holdings Limited in the Global Digital PCR Market
- 11.8.3 Key Competitors of the Company
- 11.8.4 Key Customers of the Company
- 11.8.5 Corporate Strategies
- 11.8.5.1 Synergistic Activities
- 11.8.6 Financials
- 11.8.7 Analyst Perspective
- 11.9 JN Medsys
- 11.9.1 Company Overview
- 11.9.2 Role of JN Medsys in the Global Digital PCR Market
- 11.9.3 Key Competitors of the Company
- 11.9.4 Analyst Perspective
- 11.1 Stilla
- 11.10.1 Company Overview
- 11.10.2 Role of Stilla in the Global Digital PCR Market
- 11.10.3 Key Competitors of the Company
- 11.10.4 Corporate Strategies
- 11.10.4.1 Synergistic Activities
- 11.10.5 Business Strategies
- 11.10.5.1 Product Launch/Approval
- 11.10.6 Analyst Perspective
- 11.11 Naveris, Inc.
- 11.11.1 Company Overview
- 11.11.2 Role of Naveris, Inc. in the Global Digital PCR Market
- 11.11.3 Key Competitors of the Company
- 11.11.4 Corporate strategies
- 11.11.4.1 Synergistic Activities
- 11.11.5 Analyst Perspective
- 11.12 SAGA Diagnostics
- 11.12.1 Company Overview
- 11.12.2 Role of SAGA Diagnostics in the Global Digital PCR Market
- 11.12.3 Key Competitors of the Company
- 11.12.4 Corporate strategies
- 11.12.4.1 Synergistic Activities
- 11.12.5 Analyst Perspective
- 11.13 Emerging Companies
- 11.13.1 Precigenome LLC
- 11.13.2 RevoSketch Inc.